Congenital adrenal hyperplasia: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
'''This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on [[21-hydroxylase deficiency]], [[17 alpha-hydroxylase deficiency]], [[11β-hydroxylase deficiency]], 3-beta-hydroxysteroid dehydrogenase, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia, cholesterol side-chain cleavage enzyme deficiency''' | '''This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on [[21-hydroxylase deficiency]], [[17 alpha-hydroxylase deficiency]], [[11β-hydroxylase deficiency]], 3-beta-hydroxysteroid dehydrogenase deficiency, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia, cholesterol side-chain cleavage enzyme deficiency''' | ||
. | . | ||
Line 10: | Line 10: | ||
==Overview== | ==Overview== | ||
==Classification== | ==Classification== | ||
Line 28: | Line 28: | ||
!Increased | !Increased | ||
!Decreased | !Decreased | ||
! | !Potassium levels | ||
! | ! | ||
|- | |- | ||
Line 50: | Line 50: | ||
* [[Aldosterone]] | * [[Aldosterone]] | ||
| | | | ||
* High in salt wasting type | * High in salt-wasting type | ||
* Normal in non salt wasting | * Normal in non-salt wasting | ||
| | | | ||
* CYP21A1 and CYP21A2 gene | * CYP21A1 and CYP21A2 gene | ||
Line 59: | Line 59: | ||
* Normal | * Normal | ||
| | | | ||
* Female: virilization after puberty | * Female: [[virilization]] after [[puberty]] | ||
* Male: normal appearance | * Male: normal appearance | ||
| | | | ||
Line 66: | Line 66: | ||
response to [[ACTH]] | response to [[ACTH]] | ||
| | | | ||
* Cortisol | * [[Cortisol]] | ||
* Aldosterone | * [[Aldosterone]] | ||
| | | | ||
* Normal | * Normal | ||
Line 75: | Line 75: | ||
|- | |- | ||
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]] | | align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[17 alpha-hydroxylase deficiency|17-α hydroxylase deficiency]] | ||
| | |||
* Hypertension | * [[Hypertension]] | ||
| | | | ||
* Female: normal | * Female: normal | ||
* Male: ambiguous | * Male: [[ambiguous genitalia]] | ||
| | |||
* [[Deoxycorticosterone]] | * [[Deoxycorticosterone]] | ||
* [[Corticosterone]] | * [[Corticosterone]] | ||
Line 89: | Line 89: | ||
| | | | ||
* Low | * Low | ||
| | |||
* CYP17A1 | * CYP17A1 | ||
|- | |- | ||
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | | align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[11β-hydroxylase deficiency|11-β hydroxylase deficiency]] | ||
| | |||
* Hypertension | * [[Hypertension]] | ||
| | | | ||
* Female: ambiguous | * Female: [[ambiguous genitalia]] | ||
* Male: normal or scrotal pigmentation and large phallus | * Male: normal or scrotal pigmentation and large phallus | ||
| | |||
* [[Deoxycorticosterone]] | * [[Deoxycorticosterone]] | ||
* 11-Deoxy-[[cortisol]] | * 11-Deoxy-[[cortisol]] | ||
Line 113: | Line 113: | ||
|- | |- | ||
| align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[3 beta-hydroxysteroid dehydrogenase deficiency]] | | align="center" style="padding: 5px 5px; background: #DCDCDC;" colspan="2" |[[3 beta-hydroxysteroid dehydrogenase deficiency]] | ||
| | |||
* Hypotension | * [[Hypotension]] | ||
|Both male and female: ambiguous genitalia | | | ||
* Both male and female: [[ambiguous genitalia]] | |||
| align="center" style="padding: 5px 5px; background: #F5F5F5;" | | | align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
* [[Dehydroepiandrosterone]] | * [[Dehydroepiandrosterone]] | ||
Line 213: | Line 214: | ||
* Minimal [[body hair]] | * Minimal [[body hair]] | ||
|- | |- | ||
| | |[[3 beta-hydroxysteroid dehydrogenase deficiency]] | ||
| | | | ||
* [[Dehydroepiandrosterone]] | * [[Dehydroepiandrosterone]] | ||
Line 270: | Line 271: | ||
* [[Virilization]] | * [[Virilization]] | ||
|- | |- | ||
| | |[[3 beta-hydroxysteroid dehydrogenase deficiency]] | ||
|Increased: | |Increased: | ||
* [[DHEA]] | * [[DHEA]] | ||
Line 358: | Line 359: | ||
* [[Undervirilization]] in 46,XY individuals due to a block in [[testosterone]] biosynthesis. | * [[Undervirilization]] in 46,XY individuals due to a block in [[testosterone]] biosynthesis. | ||
* Mild [[virilization]] in 46,XX individuals | * Mild [[virilization]] in 46,XX individuals | ||
|Yes in [[female]] | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Yes in [[female]] | Yes in [[female]] | ||
|Low | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Normal | Yes in [[female]] | ||
|Normal | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
Low | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
Normal | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
Normal | |||
|[[XY]] and [[XX]] | |[[XY]] and [[XX]] | ||
|- | |- | ||
Line 375: | Line 381: | ||
* Absence of secondary [[sexual characteristics]] | * Absence of secondary [[sexual characteristics]] | ||
* Minimal [[body hair]] | * Minimal [[body hair]] | ||
|No | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|No | No | ||
|Low | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Normal | No | ||
|Normal | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|[[XY]] | Low | ||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
Normal | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
Normal | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[XY]] | |||
|- | |- | ||
|[[Gonadal dysgenesis]] | |[[Gonadal dysgenesis]] | ||
Line 390: | Line 402: | ||
* [[Streak gonads]] | * [[Streak gonads]] | ||
* [[karyotyping ]] | * [[karyotyping ]] | ||
|Yes | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Yes | Yes | ||
|Low | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|High | Yes | ||
|High | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|[[XY]] | Low | ||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[XY]] | |||
|- | |- | ||
|[[Testicular regression syndrome]] | |[[Testicular regression syndrome]] | ||
Line 402: | Line 420: | ||
| | | | ||
* Female phenotype with atrophic [[Mullerian ducts]]. | * Female phenotype with atrophic [[Mullerian ducts]]. | ||
|No | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|No | No | ||
|Low | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|High | No | ||
|High | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|[[XY]] | Low | ||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[XY]] | |||
|- | |- | ||
|[[LH receptor|LH receptor defects]] | |[[LH receptor|LH receptor defects]] | ||
Line 419: | Line 443: | ||
** Unresponsiveness to [[hCG]] | ** Unresponsiveness to [[hCG]] | ||
** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]]). | ** Normal levels of [[testosterone]] precursors (produced in the [[adrenal glands]]). | ||
|No | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|No | No | ||
|Low | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|High | No | ||
|High | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|[[XY]] | Low | ||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[XY]] | |||
|- | |- | ||
|[[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]] | |[[5-alpha-reductase deficiency|5-alpha-reductase type 2 deficiency]] | ||
Line 436: | Line 466: | ||
* Defective conversion of [[testosterone]] to [[DHT]]. | * Defective conversion of [[testosterone]] to [[DHT]]. | ||
* [[Testosterone]]:[[DHT]] ratio is >10:1 | * [[Testosterone]]:[[DHT]] ratio is >10:1 | ||
|No | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|No | No | ||
|Normal male range | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|High to normal | No | ||
|High to normal | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|[[XY]] | Normal male range | ||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High to normal | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High to normal | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[XY]] | |||
|- | |- | ||
|[[Androgen insensitivity syndrome]] | |[[Androgen insensitivity syndrome]] | ||
Line 449: | Line 485: | ||
* Female [[external genitalia]] | * Female [[external genitalia]] | ||
* Resistant to [[testosterone]] | * Resistant to [[testosterone]] | ||
|No | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Yes | No | ||
|Normal male range | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Normal | Yes | ||
|Normal | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
Normal male range | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
Normal | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
Normal | |||
|[[XY]] | |[[XY]] | ||
|- | |- | ||
Line 462: | Line 503: | ||
* Normal female [[genitalia]] | * Normal female [[genitalia]] | ||
* Normal [[breast]] development | * Normal [[breast]] development | ||
|No | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Yes | No | ||
|Normal [[female]] range | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Normal | Yes | ||
|Normal | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|[[XX]] | Normal [[female]] range | ||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
Normal | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
Normal | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[XX]] | |||
|- | |- | ||
|[[Ovarian insufficiency|Primary ovarian insufficiency]] | |[[Ovarian insufficiency|Primary ovarian insufficiency]] | ||
Line 474: | Line 521: | ||
| | | | ||
* Normal [[female genitalia]] | * Normal [[female genitalia]] | ||
|Yes | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Yes | Yes | ||
|Normal female range | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|High | Yes | ||
|High | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|[[XX]] | Normal female range | ||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[XX]] | |||
|- | |- | ||
|[[Hypogonadotropic hypogonadism]] | |[[Hypogonadotropic hypogonadism]] | ||
Line 488: | Line 541: | ||
* No [[puberty]] | * No [[puberty]] | ||
|Yes | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|No | Yes | ||
|Normal female range | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Low | No | ||
|Normal | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|[[XX]] | Normal female range | ||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
Low | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
Normal | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
[[XX]] | |||
|- | |- | ||
|[[Turner syndrome]] | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
[[Turner syndrome]] | |||
| | | | ||
* Chromosomal | * Chromosomal | ||
| | | | ||
* Female [[external genitalia]] | * Female [[external genitalia]] | ||
|Yes | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|Yes | Yes | ||
|Normal [[female]] range | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
|High | Yes | ||
|High | |align="center" style="padding: 5px 5px; background: #F5F5F5;" | | ||
Normal [[female]] range | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High | |||
|align="center" style="padding: 5px 5px; background: #F5F5F5;" | | |||
High | |||
|[[Turner syndrome|45 XO]] | |[[Turner syndrome|45 XO]] | ||
|} | |} |
Revision as of 20:46, 9 August 2017
This page contains general information about Congenital adrenal hyperplasia. For more information on specific types, please visit the pages on 21-hydroxylase deficiency, 17 alpha-hydroxylase deficiency, 11β-hydroxylase deficiency, 3-beta-hydroxysteroid dehydrogenase deficiency, Cytochrome P450-oxidoreductase (POR) deficiency (ORD), congenital lipoid adrenal hyperplasia, cholesterol side-chain cleavage enzyme deficiency .
Congenital adrenal hyperplasia main page |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]
Synonyms and keywords: Congenital adrenal hyperplasia, CAH, Adrenal hyperplasia
Overview
Classification
Congenital adrenal hyperplasia is classified into seven types based on the genetic causes that lead to hyperplasia and hormonal imbalance. There are three zones of hormonal synthesis in adrenal cortex that are shown below, and impairment of each pathway may lead to a specific subtype of congenital adrenal hyperplasia.
Disease | History and symptoms | Laboratory findings | Defective gene | ||||
---|---|---|---|---|---|---|---|
Blood pressure | Genitalia | Increased | Decreased | Potassium levels | |||
21-hydroxylase deficiency | Classic type |
|
|
|
|
| |
Non-classic type |
|
|
response to ACTH |
|
| ||
17-α hydroxylase deficiency |
|
|
| ||||
11-β hydroxylase deficiency |
|
|
|
| |||
3 beta-hydroxysteroid dehydrogenase deficiency |
|
|
| ||||
Cytochrome P450-oxidoreductase (POR) deficiency (ORD) | |||||||
Congenital lipoid adrenal hyperplasia | |||||||
Cholesterol side-chain cleavage enzyme deficiency |
Differential Diagnosis
Congenital adrenal hyperplasia must be differentiated from diseases that cause ambiguous genitalia:[1][2]
Disease name | Laboratory tests | Important clinical findings | |
---|---|---|---|
Increased | Decreased | ||
Classic type of 21-hydroxylase deficiency |
|
| |
11-β hydroxylase deficiency |
|
| |
17-α hydroxylase deficiency |
| ||
3 beta-hydroxysteroid dehydrogenase deficiency |
| ||
Gestational hyperandrogenism |
|
|
Congenital adrenal hyperplasia must be differentiated from diseases that cause virilization and hirsutism in female:[3][2][4]
Disease name | Steroid status | Other laboratory | Important clinical findings |
---|---|---|---|
Non-classic type of 21-hydroxylase deficiency | Increased:
response to ACTH |
|
|
11-β hydroxylase deficiency | Increased:
Decreased: |
|
|
3 beta-hydroxysteroid dehydrogenase deficiency | Increased:
Decreased: |
|
|
Polycystic ovary syndrome |
|
|
|
Adrenal tumors |
|
|
|
Ovarian virilizing tumor |
|
|
|
Cushing's syndrome |
|
||
Hyperprolactinemia |
|
|
Some types of congenital adrenal hyperplasia must be differentiated from diseases with primary amenorrhea and female external genitalia.[5][6][7][8][9][10][11][12]
Disease name | Cause | Differentiating | ||||||
---|---|---|---|---|---|---|---|---|
Findings | Uterus | Breast development | Testosterone | LH | FSH | Karyotyping | ||
Pregnancy | HCG positive | |||||||
3-beta-hydroxysteroid dehydrogenase type 2 deficiency |
|
Yes in female |
Yes in female |
Low |
Normal |
Normal |
XY and XX | |
17-alpha-hydroxylase deficiency |
|
No |
No |
Low |
Normal |
Normal |
||
Gonadal dysgenesis |
|
|
Yes |
Yes |
Low |
High |
High |
|
Testicular regression syndrome |
|
|
No |
No |
Low |
High |
High |
|
LH receptor defects |
|
No |
No |
Low |
High |
High |
||
5-alpha-reductase type 2 deficiency |
|
No |
No |
Normal male range |
High to normal |
High to normal |
||
Androgen insensitivity syndrome |
|
|
No |
Yes |
Normal male range |
Normal |
Normal |
XY |
Mullerian agenesis |
|
No |
Yes |
Normal female range |
Normal |
Normal |
||
Primary ovarian insufficiency |
|
|
Yes |
Yes |
Normal female range |
High |
High |
|
Hypogonadotropic hypogonadism |
|
|
Yes |
No |
Normal female range |
Low |
Normal |
|
|
|
Yes |
Yes |
Normal female range |
High |
High |
45 XO |
References
- ↑ Hughes IA, Nihoul-Fékété C, Thomas B, Cohen-Kettenis PT (2007). "Consequences of the ESPE/LWPES guidelines for diagnosis and treatment of disorders of sex development". Best Pract. Res. Clin. Endocrinol. Metab. 21 (3): 351–65. doi:10.1016/j.beem.2007.06.003. PMID 17875484.
- ↑ 2.0 2.1 White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
- ↑ Hohl A, Ronsoni MF, Oliveira M (2014). "Hirsutism: diagnosis and treatment". Arq Bras Endocrinol Metabol. 58 (2): 97–107. PMID 24830586. Vancouver style error: initials (help)
- ↑ Melmed, Shlomo (2016). Williams textbook of endocrinology. Philadelphia, PA: Elsevier. ISBN 978-0323297387.=
- ↑ Maimoun L, Philibert P, Cammas B, Audran F, Bouchard P, Fenichel P, Cartigny M, Pienkowski C, Polak M, Skordis N, Mazen I, Ocal G, Berberoglu M, Reynaud R, Baumann C, Cabrol S, Simon D, Kayemba-Kay's K, De Kerdanet M, Kurtz F, Leheup B, Heinrichs C, Tenoutasse S, Van Vliet G, Grüters A, Eunice M, Ammini AC, Hafez M, Hochberg Z, Einaudi S, Al Mawlawi H, Nuñez CJ, Servant N, Lumbroso S, Paris F, Sultan C (2011). "Phenotypical, biological, and molecular heterogeneity of 5α-reductase deficiency: an extensive international experience of 55 patients". J. Clin. Endocrinol. Metab. 96 (2): 296–307. doi:10.1210/jc.2010-1024. PMID 21147889.
- ↑ Moreira AC, Leal AM, Castro M (1990). "Characterization of adrenocorticotropin secretion in a patient with 17 alpha-hydroxylase deficiency". J. Clin. Endocrinol. Metab. 71 (1): 86–91. doi:10.1210/jcem-71-1-86. PMID 2164530.
- ↑ Heremans GF, Moolenaar AJ, van Gelderen HH (1976). "Female phenotype in a male child due to 17-alpha-hydroxylase deficiency". Arch. Dis. Child. 51 (9): 721–3. PMC 1546244. PMID 999330.
- ↑ Biglieri EG (1979). "Mechanisms establishing the mineralocorticoid hormone patterns in the 17 alpha-hydroxylase deficiency syndrome". J. Steroid Biochem. 11 (1B): 653–7. PMID 226795.
- ↑ Saenger P (1996). "Turner's syndrome". N. Engl. J. Med. 335 (23): 1749–54. doi:10.1056/NEJM199612053352307. PMID 8929268.
- ↑ Bastian C, Muller JB, Lortat-Jacob S, Nihoul-Fékété C, Bignon-Topalovic J, McElreavey K, Bashamboo A, Brauner R (2015). "Genetic mutations and somatic anomalies in association with 46,XY gonadal dysgenesis". Fertil. Steril. 103 (5): 1297–304. doi:10.1016/j.fertnstert.2015.01.043. PMID 25813279.
- ↑ Imperato-McGinley J, Guerrero L, Gautier T, Peterson RE (1974). "Steroid 5alpha-reductase deficiency in man: an inherited form of male pseudohermaphroditism". Science. 186 (4170): 1213–5. PMID 4432067.
- ↑ Schnitzer JJ, Donahoe PK (2001). "Surgical treatment of congenital adrenal hyperplasia". Endocrinol. Metab. Clin. North Am. 30 (1): 137–54. PMID 11344932.